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mediocre doctors treat the disease before evident;
inferior doctors treat the full-blown disease.”
—Huang Dee: Nai-Ching (1)SEE PAGE 1789T he most common cause of death in theUnited States for more than a century, car-diovascular disease (CVD), is now the most
common cause of death worldwide. The magnitude
of the problem, coupled with a high rate of sudden
death as a ﬁrst presentation, mandates effective pri-
mary prevention. However, given the large numbers
of patients involved and the high cost of long-term
preventive treatment, efforts must be targeted to
those at highest risk. But, the questions remain:
how can we best predict risk, and what can we do
about it?
The 2013 American College of Cardiology/American
Heart Association guideline on the treatment of blood
cholesterol (2) was released simultaneously with a set
of recommendations addressing cardiovascular (CV)
risk assessment (3). The pairing provoked consider-
able controversy upon release, because the new
guidelines discarded treatment targets, setting a
relatively low threshold for treatment, and it used the
new risk algorithm on the basis of more recent multi-
ethnic data, which may misclassify a sizable percent-
age of patients. In reality, all currently available
primary prevention risk assessment tools—including
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Survey, and so on—are only moderately predictive of
CV events, as most report a c-statistic <0.80. In the
real world, this means that our current efforts at risk
prediction, even if consistently following current
recommendations, are inaccurate in millions of
individuals.An important effort to improve risk prediction
(and hopefully enhance the cost-effectiveness of
primary prevention strategies) is presented in this
issue of the Journal by Everett et al. (4), who
analyzed the relationship between N-terminal pro–B-
type natriuretic peptide (NT-proBNP) and CV events
in women without known CVD enrolled in the WHI
(Women’s Health Initiative). Although very few in-
dividuals had an NT-proBNP level above the diag-
nostic threshold for heart failure (HF) (900 ng/l),
there was a consistent, albeit modest, relationship
between NT-proBNP and incident CV events. Several
features suggest that these ﬁndings are signiﬁcant:
there was a linear relationship between risk and NT-
proBNP values; the hazard ratios were consistent
across several methods of adjustment; NT-proBNP
levels predicted each individual component of
the composite endpoint; and there were no inter-
actions with any other cardiac risk factor or patient
descriptor.
This study boasts several important strengths.
Data focusing on the utility of NT-proBNP in women
are clearly welcomed, as natriuretic peptide (NP)
values are generally higher in women and with
aging, factors that might confound these bio-
markers’ predictive ability in women. Prior data
supporting NT-proBNP as a risk predictor have been
predominantly derived from male cohorts (5).
The recent publication of 2 randomized controlled
trials (6,7) demonstrating the efﬁcacy of primary
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1799prevention strategies focused on patients with
elevated NP levels heightens the potential utility of
NP-based risk prediction. Using the WHI is also a
strength; as a large, carefully characterized cohort
with a high prevalence of events, it provides
tremendous power to investigate risk prediction in
women, who are otherwise under-represented in
current literature.
The choice of a composite of CV death, myocardial
infarction, and stroke provides a “hard” endpoint;
omitting HF is perhaps understandable because of its
potentially more subjective ascertainment. However,
given previous data clearly linking NP levels to inci-
dent HF (8), the omission is notable, because
including incident HF as an endpoint might have
further strengthened the relationship between NT-
proBNP and risk. Because subjects were not
screened for asymptomatic heart disease nor were
they excluded for a history of angina, it is unclear
whether the presence of undiagnosed structural heart
disease might, in part, explain the association be-
tween NT-proBNP and events.
Most important, though, are concerns about
implementation. Because Everett et al. (4) did not
estimate the incremental value of adding NT-proBNP
to the recently recommended atherosclerotic CVD
risk score (3), these data are hard to interpret in the
context of current guideline recommendations.
Similarly, the reclassiﬁcation analysis performed by
the authors evaluated the incremental information
provided beyond traditional risk factors and Reynolds
Risk Scores using cut points of <5%, 5% to <10%, 10%
to <20%, and >20% rather than including the
currently recommended cut point of 7.5% risk to
initiate statin therapy.
Everett et al. (4) rightly justify considering risk
prediction in men and women separately on the basis
of substantial differences between the sexes in
CVD epidemiology. Indeed, reﬁnements of risk
prediction in women can enhance reﬁned risk
algorithms in men, as application of the female-
derived Reynolds Risk Score in men shows (9).
Most importantly, the acute coronary syndromes
(ACS) literature provides ample evidence regarding
the importance of a separate consideration of
biomarkers in women. The 2007 American College of
Cardiology/American Heart Association guidelines
for the management of non-ST-elevation MI (10)
differentiates between the sexes in recommending
the use of troponin levels to decide between an
early invasive versus conservative trial in women
but not in men. Further, a multimarker approach
(combining troponin, high-sensitivity C-reactive
protein, and NT-proBNP) is more predictive whenused for ACS risk assessment in women than any
single biomarker (11).
Although the present study contributes important
information to help reﬁne risk prediction, many
questions remain, including those related to patho-
physiology and clinical translation. Although associ-
ated with many CV abnormalities, our current
understanding of NPs is that they primarily reﬂect
ventricular wall stress (12). Given that, it is unclear
why NT-proBNP should be predictive of the primary
endpoint components, especially those not clearly
etiologically related to this physiology, such as hem-
orrhagic stroke. If detection of asymptomatic atrial
ﬁbrillation (and presumably subsequent embolic
events) is the postulated mechanism for NT-proBNP’s
relationship to incident stroke (13), then what is the
causal relationship with myocardial infarction? Are
both related to asymptomatic structural heart dis-
ease? Perhaps further investigation into the under-
lying mechanism of the association will shed some
much-needed light on cardiovascular event patho-
genesis, a welcome “side effect” of efforts to improve
risk prediction.
Other questions include the potentially additive
value of using multiple versus single biomarkers and
the relative value of different types of emerging bio-
markers in this setting.
Finally, as with any diagnostic test, we must
question its impact on relevant patient-related health
and economic outcomes. The diagnostic test hierar-
chy originally proposed by Fryback and Thornbury
(14) applies here: to demonstrate efﬁcacy, an NT-
proBNP assay would need to ﬁrst demonstrate tech-
nical excellence, followed by high test performance,
then signiﬁcant changes in diagnostic thinking, and
ﬁnally, an alteration in therapeutic strategy. The ﬁrst
3 of these tenets are clearly met by NT-proBNP, and
the present study nicely validates the role of NT-
proBNP in changing diagnostic thinking in women.
However, these data cannot take us further in
implementing this knowledge to improve patient
care. Recent studies suggest that targeting intensiﬁed
CV care on the basis of NP levels can reduce events,
but these were in populations at higher risk than in
the present study (6,7). Although this is a high
evidentiary standard, it is required if we are truly to
practice evidence-based medicine in diagnostic tests
and not just medications and devices.
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